141870-95-3

Usage

Uses

Used in Pharmaceutical Industry:
(+/-)-N-CBZ-2-methylproline is used as a chiral building block for the synthesis of pharmaceuticals and biologically active compounds. Its unique structure and properties allow it to be incorporated into the development of new drugs, enhancing their efficacy and selectivity.
Used in Peptide-based Drug Preparation:
(+/-)-N-CBZ-2-methylproline is utilized in the preparation of peptide-based drugs, where it serves as a key component in the construction of peptide sequences. Its presence can influence the pharmacokinetics and pharmacodynamics of peptide therapeutics, contributing to their overall effectiveness.
Used in Materials Science:
(+/-)-N-CBZ-2-methylproline is also employed in the development of new materials, particularly in the field of materials science. Its chemical properties and reactivity make it a suitable candidate for the creation of novel materials with specific properties tailored for various applications.

Upstream product

• 1148-11-4 N-Benzyloxycarbonyl-L-proline 
• 74-88-4 methyl iodide 
• 63427-91-8 1-((benzyloxy)carbonyl)-2-methylpyrrolidine-2-carboxylic acid 
• 108645-62-1 N-benzyloxycarbonylproline methyl ester 

Downstream Products

• 51098-47-6 methyl-2-methyl-pyrrolidine-2-carboxylate 
• 141870-96-4 2-Isobutoxycarbonyloxycarbonyl-2-methyl-pyrrolidine-1-carboxylic acid benzyl ester 
• 63427-91-8 1-((benzyloxy)carbonyl)-2-methylpyrrolidine-2-carboxylic acid 

Relevant academic research and scientific papers

Synthesis and Evaluation of a Mitochondria-Targeting Poly(ADP-ribose) Polymerase-1 Inhibitor

The poly(ADP-ribose) polymerase (PARP) family of enzymes plays a crucial role in cellular and molecular processes including DNA damage detection and repair and transcription; indeed, PARP inhibitors are under clinical evaluation as chemotherapeutic adjunc

Substituted benzoxazoles

The invention relates to substituted benzoxazoles of formula (1) where R1 stands for a group of formula, and a method for preparing same and their use in the production of drugs for the treatment and/or prevention of diseases, in particular cardiovascular diseases, preferably thrombotic or thromboembolic diseases.

SATURATED FUSED [1,2-B] PYRIDAZINONE COMPOUNDS

The invention is directed to saturated fused [1,2-b]pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors

Compounds of Formula (I) inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of treatment comprising compounds of For

Preparation, Isolation and X-Ray Crystallographic Structure Determination of a Stable, Crystalline Carbonic Anhydride of an N-Protected α-Amino Acid

The reaction of methyl (2S,3aR,8aS)-2-carboxy-8-phenylsulfonyl-1,2,3,3a,8,8a-hexahydropyrrolo-indole-1-carboxylate and isobutyl chloroformate in tetrahydrofuran at -15 deg C in the presence of trimethylamine results in the formation of the correspo